This brand name is authorized in Ecuador
The drug TAFLAX contains one active pharmaceutical ingredient (API):
|
1
Dexibuprofen
UNII 671DKG7P5S - DEXIBUPROFEN
|
|
Dexibuprofen is considered to be the pharmacologically active enantiomer of racemic ibuprofen. Racemic ibuprofen is a non-steroidal substance with antiinflammatory and analgesic effects. Its mechanism of action is thought to be due to inhibition of prostaglandin synthesis. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| M01AE14 | Dexibuprofen | M Musculo-skeletal system → M01 Antiinflammatory and antirheumatic products → M01A Antiinflammatory and antirheumatic products, non-steroids → M01AE Propionic acid derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 1691-MEE-0116, H6540913, H7281013 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
